CJC-1295

This entry summarises published research. It is not guidance on use, and research-grade material is not for human or veterinary use.

Two molecules, one name

“CJC-1295” originally referred to a GHRH analogue with a drug affinity complex (DAC) attached, which makes it long-acting. Research vendors often sell a different peptide as “CJC-1295 (no DAC)”: it shares the modified GHRH(1-29) sequence but has no DAC, and is also known as Modified GRF (1-29).

What has been studied

A 2006 study in healthy adults reported prolonged rises in growth hormone and IGF-I after the DAC form. That result is specific to the DAC molecule.

Reading supplier listings

A partner certificate we reviewed is titled “CJC-1295 (no DAC)” and reports 99.884% purity and 10.33 mg in a 10 mg vial. When a vendor sells the no-DAC version, papers about the DAC form tell you little about it.

Regulatory status

Research vendors supply it as a laboratory reagent. None of the sources cited here describes it as an approved medicine, and we have not searched national registers for it. Confirm registration status with the authority in your country (see the country regulations pages).

Known limitations of the evidence

• The 2006 human study used the DAC (drug affinity complex) form; its findings do not transfer to the no-DAC peptide.
• Vendors use the name loosely, so read the certificate and the listing title carefully.

References

1. Human study Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295… J Clin Endocrinol Metab, 2006 (opens an external site in a new tab) link checked 4 Oct 2026
2. General reference Modified GRF (1-29) — Wikipedia (opens an external site in a new tab) link checked 4 Oct 2026
3. General reference CJC-1295 — Wikipedia (opens an external site in a new tab) link checked 4 Oct 2026